Pmmr Mss clinical trials

Explore recruiting pmmr mss clinical trials.

Recruiting pmmr mss studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pmmr Mss trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 or Stage III MMRp/ MSS colon cancer

Belgium, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III rectAl cancer

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer – Shaping Anti-Tumor Immunity by Oxaliplatin

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A window-of-opportunity trial with high-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colorectal cancer: the ALFEO pilot study

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study of neoadjuvant Dostarlimab in patients with untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial  -  GOIRC-02-2024

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Pmmr Mss trials by city

Pmmr Mss in Toronto Pmmr Mss in Vancouver Pmmr Mss in Montreal Pmmr Mss in Calgary Pmmr Mss in Edmonton Pmmr Mss in Ottawa Pmmr Mss in Winnipeg Pmmr Mss in Quebec City Pmmr Mss in Hamilton Pmmr Mss in Kitchener Pmmr Mss in London Pmmr Mss in Halifax Pmmr Mss in New York Pmmr Mss in Los Angeles Pmmr Mss in Chicago Pmmr Mss in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease